ArticleScientific reports2017
Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Optimizing local control in the surgical management of bladder cancer.Nature reviews. Urology · 2026Review
- The Application of Microfluidic Chips in Primary Urological Cancer: Recent Advances and Future Perspectives.Smart medicine · 2025Review
- Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response.European urology · 2024Article
- Establishment of bladder cancer spheroids and cultured in microfluidic platform for predicting drug response.Bioengineering & translational medicine · 2024Article
- Review
- Patient-Derived Bladder Cancer Organoid Models in Tumor Biology and Drug Testing: A Systematic Review.Cancers · 2022Review
- A comparative study of tumour-on-chip models with patient-derived xenografts for predicting chemotherapy efficacy in colorectal cancer patients.Frontiers in bioengineering and biotechnology · 2022Article
- Article
- Preclinical Models for Bladder Cancer Research.Hematology/oncology clinics of North America · 2021Review
- Mimicking and surpassing the xenograft model with cancer-on-chip technology.EBioMedicine · 2021Review
- Prospects and Opportunities for Microsystems and Microfluidic Devices in the Field of Otorhinolaryngology.Clinical and experimental otorhinolaryngology · 2021Review
- Cytotoxic and chemosensitizing effects of glycoalkaloidic extract on 2D and 3D models using RT4 and patient derived xenografts bladder cancer cells.Materials science & engineering. C, Materials for biological applications · 2021Article
- Patient-derived tumour models for personalized therapeutics in urological cancers.Nature reviews. Urology · 2021Review
- Article
- Fidelity of a PDX-CR model for bladder cancer.Biochemical and biophysical research communications · 2019Article
- An optical study of drug resistance detection in endometrial cancer cells by dynamic and quantitative phase imaging.Journal of biophotonics · 2019Article
- Large-scale patterning of single cells and cell clusters in hydrogels.Scientific reports · 2018Article
- Organoid models in bladder cancer: From bench to bedside?Bladder cancer (Amsterdam, Netherlands)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Precision cancer medicine seeks to target the underlying genetic alterations of cancer; however, it has been challenging to use genetic profiles of individual patients in identifying the most appropriate anti-cancer drugs. This spurred the development of patient avatars; for example, patient-derived xenografts (PDXs) established in mice and used for drug exposure studies. However, PDXs are associated with high cost, long development time and low efficiency of engraftment. Herein we explored the use of microfluidic devices or microchambers as simple and low-cost means of maintaining bladder cancer cells over extended periods of times in order to study patterns of drug responsiveness and resistance. When placed into 75 µm tall microfluidic chambers, cancer cells grew as ellipsoids reaching millimeter-scale dimeters over the course of 30 days in culture. We cultured three PDX and three clinical patient specimens with 100% success rate. The turn-around time for a typical efficacy study using microchambers was less than 10 days. Importantly, PDX-derived ellipsoids in microchambers retained patterns of drug responsiveness and resistance observed in PDX mice and also exhibited in vivo-like heterogeneity of tumor responses. Overall, this study establishes microfluidic cultures of difficult-to-maintain primary cancer cells as a useful tool for precision cancer medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.